

Expanded View Figures




Figure EV1. Schematic of *Drosophila* experimental regime and results obtained using *Drosophila* Quick Mix Blue food.

- A Parental *Drosophila* strains were crossed at 18°C and the progeny collected for 2 days post-eclosion. After 2 days together, adult male and female flies were shifted at 29°C, where they were maintained and transferred to new vials with fresh food every two days. Experimental flies were dissected at 3 and/or 7 days post-temperature shift at 29°C.
- B Representative example of DBS-S-QF activation in (red, immunostaining anti-HA) from flies reared in *Drosophila* Quick Mix Media (Blue) following the experimental regime described in (A); note the widespread activation of the DBS-S-QF reporter 7 days post-temperature shift at 29°C. DAPI (blue) labels the nuclei. Genotype: w^{1118} DBS-S-QF, UAS-*mCD8-GFP*, QUAS-*tomato-HA*.
- C Representative example of the ReDDM labelling in a *Drosophila* intestine reared in *Drosophila* Quick Mix Media (Blue) following the experimental regime described in A; *esg* expression (green, GFP) labels intestinal progenitor cells (ISCs and EBs) and Histone-RFP (red) acts as a semi-permanent marker of differentiated intestinal cells as either EEs or ECs, after the *esg* promoter is silenced. Note the high number of Histone-RFP-positive cells without GFP signal as an indication of epithelial replenishment. Genotype: w^{1118} , *esg-Gal4* UAS-CD8-GFP/Cyo; *TubG80^{TS}* UAS-Histone-RFP
- D Quantification of the ReDDM experiment shown in (C); note the significant increase of *esg* (**** $P < 0.0001$) and Histone-RFP (*** $P = 0.0004$) labelled cells (Quantifications were made using $N \geq 2$ biological replicates; unpaired two-tailed *t*-test, 3d $n = 14$, 7d $n = 34$). Error bars represent standard error of the mean. w^{1118} ; *esg-Gal4* UAS-CD8-GFP/Cyo; *TubG80^{TS}* UAS-Histone-RFP.

Figure EV2. Genome engineering of the *Dronc* locus and *Dronc* alleles.

- A Schematic diagrams showing the wild-type configuration of the *Dronc* locus before (upper lane) and after (bottom lane) targeting with CRISPR/Cas9; note the replacement of the first exon of the gene (orange box) with an attP-integration site (red box).
- B Agarose gel showing the PCR amplification of the genomic region around exon 1 of *Dronc* from larvae of the following genotypes (first lane, Wild-type +/+), heterozygous mutant flies (second lane, *Dronc*^{KO} +/-) and homozygous mutant flies (third lane, *Dronc*^{KO} -/-). Genotypes: (*w*¹¹¹⁸); (*w*¹¹¹⁸; *Dronc*^{KO}/+); (*w*¹¹¹⁸; *Dronc*^{KO}/*Dronc*^{KO}).
- C The new *Dronc*^{KO}-mutant allele is homozygous lethal in pupal stages in homozygous conditions, but also in trans-heterozygous combinations with other amorphic alleles (*Dronc*¹²⁹) as shown in the figure. Genotype: *w*¹¹¹⁸; *Dronc*^{KO}/*Dronc*¹²⁹.
- D Heterozygous *Dronc*^{KO} mutant fly (*Dronc*^{KO}/+). Genotype: *w*¹¹¹⁸; *Dronc*^{KO}/+.
- E The insertion of a wild-type cDNA of *Dronc* into the *Dronc*^{KO} allele can rescue at large extent the *Dronc* insufficiency (*Dronc*^{KO-Dronc-WT}/*Dronc*^{KO}); notice that only the adult wings were less transparent (arrow) than in the heterozygous controls (d) and sometimes are improperly extended. Genotype: *w*¹¹¹⁸; *Dronc*^{KO}/*Dronc*^{KO-FL-DroncWT-Suntag-HA}.
- F-L Plasmid configuration of the different constructs inserted into the *Dronc*^{KO} attP site.
- M Western blot showing the expression of FLWT (*Dronc*^{KO-FLWT-suntag-HA-Cherry}/+), FLCAEA (*Dronc*^{KO-FLCAEA-suntag-HA-Cherry}/+) and dCAEA (*Dronc*^{KO-dCAEA-suntag-HA-Cherry}/+) constructs inserted into the endogenous *Dronc* locus, note that each of the constructs appear to be expressed at the same levels. Genotypes: (*w*¹¹¹⁸; *Dronc*^{KO-FLWT-suntag-HA-Cherry}/+), (*w*¹¹¹⁸; *Dronc*^{KO-FLCAEA-suntag-HA-Cherry}/+); (*w*¹¹¹⁸; *Dronc*^{KO-dCAEA-suntag-HA-Cherry}/+).
- N Plasmid configuration of a Gal4 constructs inserted into the *Dronc*^{KO} attP site.




Figure EV2.

Figure EV3. *Dronc* functions are related to its enzymatic activity.

- A Representative image of a *Dronc* WT intestine, reared in Oxford Medium under an experimental regime which protects epithelial integrity, showing ReDDM activation for 7 days post-temperature shift at 29°C. The Flippase-mediated excision of the FRT-flanked wild-type cDNA of *Dronc* allows the expression of a wild-type construct of *Dronc* tagged with Suntag, HA and cherry that does not cause epithelial alterations. DAPI (blue) labels the nuclei in all the figure. Genotype: $w^{1118}; esg-Gal4$ UAS-*CD8-GFP/+*; *TubG80^{ES}* UAS-*Histone-RFP Dronc^{KO}*/UAS-*Flippase FRT Dronc-GFP-APEX FRT Dronc-FLWT-suntag-HA-Cherry*.
- B Representative image of a *Dronc* heterozygous intestine (see full genotype description in Materials and Methods), reared in Oxford Medium under an experimental regime which protects epithelial integrity, showing ReDDM activation for 7 days post-temperature shift at 29°C; *esg* expression (green) labels the intestinal progenitor cells, *Histone-RFP* (red) is a semi-permanent marker retained in differentiated cells. Genotype: $w^{1118}; esg-Gal4$ UAS-*CD8-GFP/+*; *TubG80^{ES}* UAS-*Histone-RFP Dronc^{KO}*/+.
- C Representative image of ReDDM labelling showing a *Dronc*-mutant intestine, expressing a catalytically inactive form of *Dronc* (FLCA) in progenitor cells (*esg*-positive cells, green) in a *Dronc* KO genetic background for 7 days post-temperature shift at 29°C; notice that *esg*-labelled cells appear enlarged and guts appear hyperplastic compared with (A). Genotype: $w^{1118}; esg-Gal4$ UAS-*CD8-GFP/+*; *TubG80^{ES}* UAS-*Histone-RFP Dronc^{KO}*/UAS-*Flippase FRT Dronc-FLCA-suntag-HA-Cherry*.
- D Representative image of ReDDM labelling showing a *Dronc* mutant intestine expressing in progenitor cells (*esg*-positive cells, green) a catalytically inactive and non-cleavable form of *Dronc* (FLCAEA) in a heterozygous KO *Dronc* mutant genetic background for 7 days post-temperature shift at 29°C; notice that *esg*-labelled cells appear enlarged and guts appear hyperplastic compared with (A). Genotype: $w^{1118}; esg-Gal4$ UAS-*CD8-GFP/+*; *TubG80^{ES}* UAS-*Histone-RFP Dronc^{KO}*/UAS-*Flippase FRT Dronc-FLCAEA-suntag-HA-Cherry*.
- E Equivalent to the experiment described in (B) and (C) but in this case *esg*-progenitor cells are forced to express a catalytically inactive form of *Dronc* without the CARD domain (delta-CAEA, dCAEA). Genotype: $w^{1118}; esg-Gal4$ UAS-*CD8-GFP/+*; *TubG80^{ES}* UAS-*Histone-RFP Dronc^{KO}*/UAS-*Flippase FRT Dronc-GFP-APEX FRT Dronc-delta-CAEA-suntag-HA-Cherry*.
- F Quantification of the percentage of *esg*-expressing cells relative to DAPI; note the increase of *esg*-expressing cells in the different mutant conditions in comparison with a *Dronc* heterozygous mutant background (FLCA, **** $P < 0.0001$; FLCAEA * $P = 0.0212$; Δ CAEA, **** $P < 0.0001$) (Quantifications were made using $N \geq 2$ biological replicates; Dunnett's multiple comparisons test, +/- $n = 61$, -/FLCA $n = 21$ -/FLCAEA $n = 26$, -/ Δ CAEA $n = 37$). Error bars represent standard deviation of the mean. Quantifications in graph refer to genotypes from (A–E).
- G Quantification of average cell size of *esg*-expressing cells (μm^2 ; FLCA, *** $P = 0.0002$; FLCAEA, *** $P = 0.0007$; Δ CAEA, ** $P = 0.0058$) (Quantifications were made using $N \geq 2$ biological replicates; Dunnett's multiple comparisons test, +/- $n = 61$, -/FLCA $n = 23$, -/FLCAEA $n = 26$, -/ Δ CAEA $n = 37$). Error bars represent standard deviation of the mean. Quantifications in graph refer to genotypes from (A–E).
- H Quantification of the percentage of *Histone-RFP* cells without GFP signal relative to DAPI; notice that the number of cells only expressing *Histone-RFP* is significantly higher in the FLCA (**** $P < 0.0001$), FLCAEA (**** $P < 0.0001$) and Δ CAEA (*** $P = 0.0001$) genetic backgrounds (Quantifications were made using $N \geq 2$ biological replicates; Dunnett's multiple comparisons test, +/- $N = 39$, -/FLCA $n = 16$, -/FLCAEA $n = 19$, -/ Δ CAEA $n = 14$). Error bars represent standard deviation of the mean. Quantifications in graph refer to genotypes from (A–E).




Figure EV3.




Figure EV4. *Dronc* regulates EB cellular properties independently of the effector caspases and upstream pro-apoptotic factors.

- A** 7d post-temperature shift to 29°C. *Dronc* heterozygous intestine. All of the experiments described in the figure were performed in Oxford medium following an experimental regime which protects epithelial integrity. *esg*-Gal4 UAS-GFP labels ISCs and EBs in the panel A–C, E and F. Genotypes: w^{1118} ; *esg*-Gal4 UAS-*CD8-GFP/+*; *TubG80^{ts}* UAS-*Histone-RFP Dronc^{KO/+}*.
- B** The overexpression of two copies of the effector caspase activity inhibitor (P35) under the regulation of *esg*-Gal4 does not cause morphological defects or an increase in cell size of intestinal progenitor cells ($P = 0.8307$). Genotypes: w^{1118} ; *esg*-Gal4 UAS-*CD8-GFP/UAS-P35*; *TubG80^{ts}* UAS-*Histone-RFP Dronc^{KO}/UAS-P35*.
- C** Concomitant overexpression of RNAi against all known *Drosophila* effector caspases under the regulation of *esg*-Gal4. The knockdown of all effector caspases fails to recapitulate the increase in cell size observed following loss of *Dronc* ($P = 0.0002$). Genotype: w^{1118} ; *esg*-Gal4 UAS-*CD8-GFP/UAS-Drice RNAi UAS-Decay RNAi* (Pascal Meier); *TubG80^{ts}* UAS-*Histone-RFP Dronc^{KO}/UAS-Damm RNAi UAS-DCP1 RNAi* (Pascal Meier).
- D** Quantification of average *esg* cell size (μm^2) (n.s. $P > 0.5$; *** $P = 0.001$) (Quantifications were made using $N \geq 2$ biological replicates; Dunn's multiple comparisons test, +/- $n = 25$, 2 × P35 $n = 11$, Effector Caspase RNAi $N = 16$). Error bars represent standard deviation of the mean. Quantifications in graph refer to genotypes from (A–C).
- E** The overexpression of RNAi against Dark. There is not significant change in cell size compared with +/- ($P = 0.2222$). Genotype: w^{1118} ; *esg*-Gal4 UAS-*CD8-GFP/+*; *TubG80^{ts}* UAS-*Histone-RFP Dronc^{KO}/UAS-Dark RNAi* (BL33924).
- F** Overexpression of a miRNA against the pro-apoptotic factors, hid, reaper and grim. Note, the inhibition of these factors does not result in any noticeable phenotypes (ns; $P = 0.0521$). Genotype: w^{1118} ; *esg*-Gal4 UAS-*CD8-GFP/+*; *TubG80^{ts}* UAS-*Histone-RFP Dronc^{KO}/UAS-miRNA-RHG* (I. Hariharan).
- G** Quantification of average *esg* cell size (μm^2). There is no increase in cell size following overexpression of two different Dark RNAis (n.s. $P = 0.2222$ and ** $P = 0.0020$) or a miRNA against the pro-apoptotic factors (n.s. $P = 0.0521$) (Quantifications were made using $N \geq 2$ biological replicates; Dunn's multiple comparisons test, +/- $n = 36$, *esg* > Dark RNAi (1) $n = 17$, *esg* > Dark RNAi (2) $n = 16$, *esg* > RHG miRNA $n = 35$). Error bars represent standard deviation of the mean. Quantifications in graph refer to genotypes from Fig 4E and F and an extra Dark RNAi (VDR35122).